Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Inhibrx Biosciences (INBX) Shares Outstanding (Diluted Average): 2023-2025

Historic Shares Outstanding (Diluted Average) for Inhibrx Biosciences (INBX) over the last 3 years, with Sep 2025 value amounting to $15.5 million.

  • Inhibrx Biosciences' Shares Outstanding (Diluted Average) rose 0.06% to $15.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $15.5 million, marking a year-over-year increase of 0.06%. This contributed to the annual value of $15.0 million for FY2024, which is 27.17% up from last year.
  • As of Q3 2025, Inhibrx Biosciences' Shares Outstanding (Diluted Average) stood at $15.5 million, which was up 0.06% from $15.5 million recorded in Q2 2025.
  • Over the past 5 years, Inhibrx Biosciences' Shares Outstanding (Diluted Average) peaked at $15.5 million during Q3 2025, and registered a low of $10.9 million during Q2 2023.
  • Moreover, its 3-year median value for Shares Outstanding (Diluted Average) was $14.9 million (2024), whereas its average is $14.0 million.
  • Data for Inhibrx Biosciences' Shares Outstanding (Diluted Average) shows a peak YoY skyrocketed of 35.71% (in 2024) over the last 5 years.
  • Inhibrx Biosciences' Shares Outstanding (Diluted Average) (Quarterly) stood at $11.8 million in 2023, then rose by 27.17% to $15.0 million in 2024, then rose by 0.06% to $15.5 million in 2025.
  • Its Shares Outstanding (Diluted Average) stands at $15.5 million for Q3 2025, versus $15.5 million for Q2 2025 and $15.5 million for Q1 2025.